Sex Difference of Coronary Microvascular Dysfunction in Patients With Non-obstructive Coronary Artery Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20-80
SponsorKorea University Anam Hospital

About this trial

Sex difference of coronary microvascular dysfunction evaluated by coronary flow reserve will be assessed in patients with non-obstructive coronary artery disease

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Typical/atypical chest pain or ischemic symptoms including dyspnea

No significant coronary artery stenosis (<50% stenosis) in coronary angiography or computed tomography

Disqualifiers

≥ Moderate valvular heart disease

Congenital heart disease

Chronic renal failure (estimated glomerular filtration rate <30 ml/min/1.73m2) or end-stage renal failure undergoing hemodialysis or peritoneal dialysis

Asthma, chronic obstructive pulmonary disease and primary pulmonary hypertension

Trial population

Consecutive patients who experienced chest pain but with no obstructed coronary arteries (\<50% stenosis)

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Adenosine stress echocardiography

    Diagnostic test

    Transthoracic echocardiographic assessments will be performed using an ultrasound device (Vivid E95, General Electric Healthcare, Liestal, Switzerland). Color Doppler flow of the distal left anterior descending artery was examined from the modified apical four-chamber view of the anterior interventricular groove. Pulsed-wave Doppler registered blood flow velocity patterns using a sample volume (2-3.0 mm) placed on the color signal. The ultrasound beam was aligned parallel to the vessel flow. The velocity scale of color Doppler was set to 0.21 m/s. Coronary flow Doppler images were acquired at baseline and at 1, 2, and 3 min after adenosine infusion in the same part of the artery. Anti-anginal medications, including calcium channel blockers, were discontinued before the study.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

A composite outcome including all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure

Number of participants with a composite outcome including all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure

Time frame
1 year

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.